ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy – GlobeNewswire

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Companys Scientific Advisory Board (SAB) with new members. The SAB members serve as strategic advisors to the Company as it continues to advance its pipeline of RNA therapeutics and its proprietary technology platforms.

We are strengthening our Scientific Advisory Board with the addition of leading experts in inherited retinal disease and RNA therapies, said Daniel A. de Boer, Chief Executive Officer of ProQR. These individuals bring important scientific, medical, and industry experience, as well as diverse perspectives for us to draw upon. Im excited to work with this distinguished and talented group of advisors and believe their contributions will be significant as we continue advancing our platform for patients living with Inherited Retinal Diseases.

ProQRs SAB is comprised of:

Biographies for the SAB members are available on ProQRs website.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. *Since 2012*

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such statements include, but are not limited to, statements regarding our SAB members, and statements regarding our ongoing and planned discovery and development of our pipeline and the advancement of our novel and proprietary technologies.Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor Contact:Sarah KielyProQR Therapeutics N.V.T: +1 617 599 6228skiely@proqr.comorHans VitzthumLifeSci AdvisorsT: +1 617 535 7743hans@lifesciadvisors.com

Media Contact:Sara ZelkovicLifeSci Public RelationsT: +1 646 876 4933sara@lifescipublicrelations.com